查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466354

吸入和鼻噴霧的學名藥市場：按適應症、年齡層、藥物類別、途徑和分銷管道 - 2024 年至 2030 年全球預測

Inhalation & Nasal Sprays Generic Drugs Market by Indication (Allergic Rhinitis, Asthma, COPD), Age Group (Adults, Children 2 to 5, Children 6 to 12), Class, Route, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

學名藥藥吸入和鼻噴霧市場規模預計到 2023 年為 80.9 億美元，2024 年達到 87.8 億美元，2030 年達到 144.3 億美元，複合年成長率預計為 8.61%。

學名藥吸入器和鼻噴霧是專利到期藥物，與品牌藥物具有生物等效性。學名藥含有相同的活性成分，透過相同的給藥途徑給藥，並旨在提供與品牌藥相同的治療效果。這些學名藥通常是在品牌藥的獨佔專利期結束後生產的，價格通常較低，因此可廣泛用於治療呼吸道疾病、過敏和其他鼻腔或肺部問題。吸入器和鼻噴霧的學名藥市場主要是由呼吸系統疾病盛行率的增加、學名藥的成本效益以及品牌藥的專利到期的。此外，新興市場的可近性提高以及對小病自我治療的接受程度提高也有助於市場成長。然而，需要大量文件和臨床試驗的嚴格法律規範可能會延遲產品的商業化。來自品牌藥物的競爭、有限的醫療預算和價格壓力也是非專利藥吸入器和鼻噴霧業務的主要障礙。儘管存在這些挑戰，具有更好的給藥系統和患者依從性方面的生物等學名藥的研究和開發有望帶來潛在的成長。醫療基礎設施不斷改善的新興經濟體為學名藥藥吸入器和鼻噴霧製造商提供了利潤豐厚的機會。

主要市場統計
基準年[2023] 80.9億美元
預測年份 [2024] 87.8億美元
預測年份 [2030] 144.3億美元
複合年成長率（%） 8.61%

適應症需要學名藥來快速、即時緩解過敏性鼻炎症狀

過敏性鼻炎是由於接觸過敏原誘發IgE介導的發炎而引起的發炎疾病，並伴隨打噴嚏、搔癢、鼻塞、流鼻水等症狀。含有皮質類固醇和抗組織胺藥物的學名藥滴鼻劑噴劑被廣泛用於控制和緩解這些症狀。氣喘是一種慢性發炎疾病，會導致氣流阻塞和支氣管痙攣。吸入性學名藥（例如支氣管擴張劑和吸入性皮質類固醇）對於治療這種情況至關重要。慢性阻塞性肺病是一組以呼吸急促加劇為特徵的進行性肺部疾病。支氣管擴張劑、吸入性皮質類固醇和磷酸二酯酶 4 抑制劑等學名藥用於吸入治療 COPD。

年齡層：針對2至5歲兒童的產品開發不斷增加

使用學名藥吸入器和滴鼻劑的成年使用者通常會尋求氣喘、慢性阻塞性肺病(COPD) 和過敏性鼻炎的治療。對這一人群來說，藥物療效、使用便利性和成本效益是基於需求的偏好。兒童兒童，尤其是 2 至 5 歲的兒童，需要更安全、劑量更低且專門針對其年齡層的吸入器和鼻噴霧。兒童用配方通常更偏好並且具有適合年齡的遞送機制。與年齡較小的兒童族群一樣，6 至 12 歲的兒童需要安全的、兒童專用劑量的吸入器和滴鼻劑。然而，這個年齡層的兒童自我使用某些類型吸入器的能力越來越強，例如定量吸入器 (MDI)。

分銷管道：提供有競爭力的價格和便利性的網路藥局日益普及

醫院醫療商店是取得學名藥吸入器和滴鼻劑的重要中心，為住院患者提供即時，並為出院患者和就診患者提供便利。這些商店主要滿足緊急和急診需求，其中即時給藥至關重要。網路藥局是一個不斷成長的學名藥分銷管道，提供便利且價格往往具有競爭力。網路藥局迎合了精通科技的消費者，他們重視自由裁量權，尤其是管理可能被污名化的疾病或需要定期長期用藥的慢性病。對於需要吸入器和滴鼻劑等學名藥的患者來說，零售藥局是最常見、最方便的銷售點。零售藥局滿足急性和慢性治療需求，並且是快速取得的首選，特別是當線上交付時間表或醫院地點不方便時。

區域洞察

美洲吸入器和鼻噴霧學名藥市場受到包括慢性阻塞性肺病（COPD）和氣喘在內的呼吸系統疾病的高盛行率、有利的報銷政策和發達的醫療基礎設施的推動，採用正在擴大。重磅吸入器的專利到期以及製造商之間的競爭加劇，使得學名藥藥的進入變得更便宜。美國肺臟協會等團體的努力也有助於提高人們對呼吸道疾病的認知，進一步增加對吸入器和鼻噴霧的需求。由於經濟、監管和醫療保健環境的差異，歐洲、中東和非洲地區呈現多樣化的市場動態。歐洲市場相對成熟，強調高品質的醫療保健，監管嚴格，有助於非專利藥吸入和鼻噴霧市場的穩定成長。中東和非洲是具有巨大成長潛力的新興市場。隨著醫療保健成本的增加，成本控制措施推動了歐洲學名藥的採用增加。在中東和非洲，醫療基礎設施的改善和藥物取得的增加正在推動市場成長。在非專利行業擴張和醫療保健成本上升的推動下，預計亞太地區學名藥藥吸入器和鼻噴霧市場的成長率最高。政府推廣學名藥的舉措以及製藥公司建立生產設施也是亞太地區學名藥藥吸入器和鼻噴霧市場未來的積極指標。

FPNV定位矩陣

FPNV 定位矩陣對於評估學名藥藥吸入劑和鼻噴霧市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對學名藥藥吸入和鼻噴霧市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1. 吸入器和鼻噴霧的學名藥市場規模和預測是多少？

2.在學名藥藥吸入和鼻噴霧市場預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.吸入器和鼻噴霧學名藥市場的技術趨勢和法規結構是什麼？

4.學名藥藥吸入/鼻噴霧市場主要供應商的市場佔有率是多少？

5.進入吸入器和鼻噴霧學名藥市場的適當型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 學名藥成本低
      • 呼吸道疾病盛行率增加
      • 兒童用霧化器重要介紹
    • 抑制因素
      • 對學名藥的嚴格監管
    • 機會
      • 重磅藥物專利到期和 FDA核准增加
      • 藥廠加大研發投入
    • 任務
      • 多個參與者的存在增加了價格壓力
  • 市場區隔分析
    • 適應症：需要使用治療過敏性鼻炎的學名藥即時、立即緩解症狀
    • 年齡層：加強2~5歲兒童產品研發
    • 分銷管道：網路藥局變得越來越受歡迎，因為它們提供有競爭力的價格和便利性。
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化
    • 處方和給藥裝置的變更

第6章 吸入器和鼻噴霧的學名藥市場

  • 過敏性鼻炎
  • 氣喘
  • 慢性阻塞性肺病

第7章 吸入器和鼻噴霧的學名藥市場：按年齡層

  • 成人
  • 2歲至5歲兒童
  • 6至12歲兒童

第8章吸入器和鼻噴霧的學名藥市場：按類別

  • 過敏阻斷劑
  • 抗膽鹼能藥
  • 抗組織胺藥
  • 減充血劑
  • 肥大細胞抑制劑
  • 鼻類固醇

第9章 吸入器和鼻噴霧的學名藥市場：按途徑

  • 吸入
  • 鼻噴劑
  • 熱帶乳液

第10章吸入器和鼻噴霧的學名藥市場：按配銷通路

  • 醫院醫療用品店
  • 網路藥房
  • 藥局零售業

第11章 美洲吸入器和鼻噴霧的學名藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章 亞太地區吸入器和鼻噴霧學名藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲吸入器和鼻噴霧學名藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Usea Pharma 學名藥布非專利Budesonide獲得美國FDA核准
    • Amphastar Pharmaceuticals 的鹽酸納洛酮鼻滴鼻劑4 毫克獲得 FDA核准
    • Amneal 宣布其鹽酸納洛酮滴鼻劑（USP，4 mg）的簡化新藥申請已被美國FDA 受理

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-032A67D9141A

[190 Pages Report] The Inhalation & Nasal Sprays Generic Drugs Market size was estimated at USD 8.09 billion in 2023 and expected to reach USD 8.78 billion in 2024, at a CAGR 8.61% to reach USD 14.43 billion by 2030.

Inhalation and nasal sprays generic drugs are off-patent pharmaceuticals that are bioequivalent to their branded counterparts. They contain the same active ingredients, are administered through the same route of administration, and are intended to have the same therapeutic effect as the original medications. These generic medications are often produced following the original drug's exclusive patent period and are typically offered at a lower cost, enabling wider accessibility to patients requiring treatment for respiratory conditions, allergies, and other nasal or pulmonary issues. The market for inhalation and nasal spray generic drugs is primarily driven by the increasing prevalence of respiratory diseases, the cost-effectiveness of generic products, and patent expiries of branded drugs. Enhanced accessibility in emerging markets and growing acceptance of self-medication for minor ailments also contribute to market growth. However, stringent regulatory frameworks that necessitate extensive documentation and clinical trials potentially delay product commercialization. Competition from branded drugs, limited healthcare budgets, and pricing pressures also pose significant hurdles for inhalation and nasal spray generic businesses. Despite the challenges, research and development in bioequivalent generic drugs with better delivery systems and patient compliance aspects promise potential growth. Developing economies with improving healthcare infrastructure present lucrative opportunities for generic inhalation and nasal spray generic drug manufacturers.

KEY MARKET STATISTICS
Base Year [2023] USD 8.09 billion
Estimated Year [2024] USD 8.78 billion
Forecast Year [2030] USD 14.43 billion
CAGR (%) 8.61%

Indication: Need for quick and immediate symptom relief generic medications for allergic rhinitis

Allergic rhinitis is an inflammatory condition caused by allergen exposure that triggers IgE-mediated inflammation, with symptoms such as sneezing, itching, nasal congestion, and rhinorrhea. Generic drugs in the form of nasal sprays, including corticosteroids and antihistamines, are widely used to manage and relieve these symptoms. Asthma, a chronic inflammatory disease, leads to airflow obstruction and bronchospasm. Inhalation of generic drugs, including bronchodilators and inhaled corticosteroids, are essential in the management of this condition. Chronic obstructive pulmonary disease is a group of progressive lung diseases characterized by increasing breathlessness. Generic medications, including bronchodilators, inhaled corticosteroids, and phosphodiesterase-4 inhibitors, are used inhaled to manage COPD.

Age Group: Increasing product development for children aged 2 to 5

Adult users of inhalation and nasal spray generic drugs commonly seek treatment for asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. For this demographic, medication effectiveness, convenience of use, and cost-effectiveness are need-based preferences. The pediatric population, particularly those aged 2 to 5, require inhalation and nasal sprays that are safe, have a lower dosage, and are tailored specifically for their age group. Pediatric formulations are often designed to be more palatable and come with age-appropriate delivery mechanisms. Similar to the younger pediatric group, children aged 6 to 12 require inhalation and nasal sprays that are safe and specifically dosed for them. However, the capacity for children in this age bracket to manage certain inhaler types themselves, such as metered-dose inhalers (MDIs), increases.

Distribution Channel: Growing popularity of online pharmacies offering competitive pricing and convenience

Hospital medical stores are critical points of access for inhalation and nasal spray generic drugs, providing immediacy to in-patients and convenience to those being discharged or visiting for appointments. These stores primarily cater to the need for emergency care and acute treatments where the immediate administration of the medication is imperative. Online pharmacies represent a growing distribution channel for generic drugs, offering convenience and often competitive pricing. They cater to tech-savvy consumers who value discretion, particularly for conditions that may carry a stigma or for managing chronic conditions that require regular, long-term medication regimens. Retail pharmacies are the most common and accessible outlets for patients requiring inhalation and nasal spray generic drugs. They cater to both acute and chronic treatment needs and are a preferred choice for immediate access, especially when online delivery timelines or hospital locations are not convenient.

Regional Insights

The market for inhalation and nasal spray generic drugs in the Americas has been demonstrating growing adoption, with a high prevalence of respiratory disorders, including chronic obstructive pulmonary disease (COPD) and asthma, favorable reimbursement policies, and a well-established healthcare infrastructure. The entry of generic drugs has been supported by patent expirations of blockbuster inhalation drugs, intensifying competition among manufacturers and thus making medications more affordable. Initiatives by organizations, including the American Lung Association, also aid in increasing awareness about respiratory conditions, further driving the demand for inhalation and nasal sprays. The EMEA region exhibits diverse market dynamics owing to varying economic, regulatory, and healthcare environments. The European market is relatively mature, with a strong emphasis on high-quality healthcare and the presence of stringent regulations, contributing to a steady growth in the generic inhalation and nasal spray market. The Middle East and Africa present a nascent market with potential for significant growth. The rise in generic drug adoption in Europe is propelled by cost-containment measures amidst increasing healthcare costs. In the Middle East and Africa, improvements in healthcare infrastructure and increasing access to medicines are catalyzing market growth. The Asia-Pacific is anticipated to exhibit the highest growth rate in the inhalation and nasal spray generic drugs market, bolstered by an expanding generic industry, growing healthcare expenditure. Government initiatives to promote generic medications and the establishment of production facilities by pharmaceutical companies are also positive indicators for the future of the inhalation and nasal spray generic drugs market in APAC.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Inhalation & Nasal Sprays Generic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Inhalation & Nasal Sprays Generic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Inhalation & Nasal Sprays Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Acerus Pharmaceuticals Corporation, Akorn, Inc., Altaire Pharmaceuticals Inc., Amphastar Pharmaceuticals, Inc., Apotex Inc., AptarGroup, Inc., AstraZeneca PLC, Beximco Pharmaceuticals Ltd., Catalent, Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Mylan N.V., Nephron Pharmaceuticals Corporation, Nippon Shinyaku Co., Ltd., Padagis US LLC, Perrigo Company PLC, Preferred Pharmaceuticals, Inc., Recipharm AB, Sandoz International GmbH, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zhejiang Xianju Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Inhalation & Nasal Sprays Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Allergic Rhinitis
    • Asthma
    • COPD
  • Age Group
    • Adults
    • Children 2 to 5
    • Children 6 to 12
  • Class
    • Allergy Blocker
    • Anticholinergic
    • Antihistamine
    • Decongestant
    • Mast Cell Inhibitor
    • Nasal Steroid
  • Route
    • Inhalation
    • Nasal Spray
    • Tropical Lotion
  • Distribution Channel
    • Hospital Medical Store
    • Online Pharmacy
    • Pharmacy Retail
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Inhalation & Nasal Sprays Generic Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Inhalation & Nasal Sprays Generic Drugs Market?

3. What are the technology trends and regulatory frameworks in the Inhalation & Nasal Sprays Generic Drugs Market?

4. What is the market share of the leading vendors in the Inhalation & Nasal Sprays Generic Drugs Market?

5. Which modes and strategic moves are suitable for entering the Inhalation & Nasal Sprays Generic Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Low Cost Involved with Generic Prescription Drugs
      • 5.1.1.2. Increasing Prevalence of Respiratory Diseases
      • 5.1.1.3. Significant Adoption of Nebulizers for Children
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent Regulations For Generic Drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Patent Expiry of Blockbuster Drugs and Increasing FDA Approvals
      • 5.1.3.2. Growing Investments from Pharmaceutical Companies for R&D
    • 5.1.4. Challenges
      • 5.1.4.1. Pricing Pressure due to Presence of Multiple Players in the Segment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication: Need for quick and immediate symptom relief generic medications for allergic rhinitis
    • 5.2.2. Age Group: Increasing product development for children aged 2 to 5
    • 5.2.3. Distribution Channel: Growing popularity of online pharmacies offering competitive pricing and convenience
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization
    • 5.9.1. Changing Formulation & Delivery Device

6. Inhalation & Nasal Sprays Generic Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Allergic Rhinitis
  • 6.3. Asthma
  • 6.4. COPD

7. Inhalation & Nasal Sprays Generic Drugs Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Children 2 to 5
  • 7.4. Children 6 to 12

8. Inhalation & Nasal Sprays Generic Drugs Market, by Class

  • 8.1. Introduction
  • 8.2. Allergy Blocker
  • 8.3. Anticholinergic
  • 8.4. Antihistamine
  • 8.5. Decongestant
  • 8.6. Mast Cell Inhibitor
  • 8.7. Nasal Steroid

9. Inhalation & Nasal Sprays Generic Drugs Market, by Route

  • 9.1. Introduction
  • 9.2. Inhalation
  • 9.3. Nasal Spray
  • 9.4. Tropical Lotion

10. Inhalation & Nasal Sprays Generic Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Medical Store
  • 10.3. Online Pharmacy
  • 10.4. Pharmacy Retail

11. Americas Inhalation & Nasal Sprays Generic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Inhalation & Nasal Sprays Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Inhalation & Nasal Sprays Generic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Eugia Pharma Gets USFDA Nod for Budesonide Generic
    • 14.3.2. Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
    • 14.3.3. Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COPD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 2 TO 5, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 2 TO 5, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 6 TO 12, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 6 TO 12, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGY BLOCKER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGY BLOCKER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DECONGESTANT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DECONGESTANT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY MAST CELL INHIBITOR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY MAST CELL INHIBITOR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL STEROID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL STEROID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY TROPICAL LOTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY TROPICAL LOTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY HOSPITAL MEDICAL STORE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY HOSPITAL MEDICAL STORE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PHARMACY RETAIL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PHARMACY RETAIL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRI